82 related articles for article (PubMed ID: 10087314)
1. Analysis of antibodies to p16INK4A tumor suppressor gene products in lung cancer patients.
Namikawa O; Shimizu E; Sumitomo K; Sone S
Int J Oncol; 1999 Apr; 14(4):681-5. PubMed ID: 10087314
[TBL] [Abstract][Full Text] [Related]
2. Presence of antibodies against retinoblastoma tumor suppressor protein in patients with lung cancer.
Matsumoto S; Teramoto H; Nakamoto M; Igishi T; Kawasaki Y; Shimizu E
Int J Oncol; 2001 Nov; 19(5):1035-9. PubMed ID: 11605006
[TBL] [Abstract][Full Text] [Related]
3. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients.
Yamamoto A; Shimizu E; Ogura T; Sone S
Int J Cancer; 1996 Aug; 69(4):283-9. PubMed ID: 8797869
[TBL] [Abstract][Full Text] [Related]
4. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
[TBL] [Abstract][Full Text] [Related]
5. p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer.
Vonlanthen S; Heighway J; Kappeler A; Altermatt HJ; Borner MM; Betticher DC
Int J Oncol; 2000 May; 16(5):951-7. PubMed ID: 10762631
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
7. p16Ink4a suppression of lung adenocarcinoma by Bmi-1 in the presence of p38 activation.
Lee MO; Lee HJ; Kim MA; Kim EK; Lee JH; Heo JH; Lee SH; Cho SH; Fornace AJ; Jeong HC; Cha HJ
J Thorac Oncol; 2011 Mar; 6(3):423-31. PubMed ID: 21164364
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
[TBL] [Abstract][Full Text] [Related]
9. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients.
Yamamoto A; Shimizu E; Takeuchi E; Houchi H; Doi H; Bando H; Ogura T; Sone S
Oncology; 1999; 56(2):129-33. PubMed ID: 9949299
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Role of RASSF1A and p16INK4a Promoter Gene Hypermethylation in Serum DNA of Lung Cancer Patients: Clinicopathological Significance.
El-Sherif WT; Sayed SK; Galal SH; Makhlouf HA; Hassan AT; Yousef HA
Egypt J Immunol; 2016 Jun; 23(2):1-16. PubMed ID: 28502129
[TBL] [Abstract][Full Text] [Related]
11. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer.
Toyooka S; Maruyama R; Toyooka KO; McLerran D; Feng Z; Fukuyama Y; Virmani AK; Zochbauer-Muller S; Tsukuda K; Sugio K; Shimizu N; Shimizu K; Lee H; Chen CY; Fong KM; Gilcrease M; Roth JA; Minna JD; Gazdar AF
Int J Cancer; 2003 Jan; 103(2):153-60. PubMed ID: 12455028
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
13. Detection of aberrant p16INK4A methylation in sera of patients with liver cirrhosis and hepatocellular carcinoma.
Chu HJ; Heo J; Seo SB; Kim GH; Kang DH; Song GA; Cho M; Yang US
J Korean Med Sci; 2004 Feb; 19(1):83-6. PubMed ID: 14966347
[TBL] [Abstract][Full Text] [Related]
14. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Shapiro GI; Park JE; Edwards CD; Mao L; Merlo A; Sidransky D; Ewen ME; Rollins BJ
Cancer Res; 1995 Dec; 55(24):6200-9. PubMed ID: 8521414
[TBL] [Abstract][Full Text] [Related]
15. Activation of RB tumor suppressor protein and growth suppression of small cell lung carcinoma cells by reintroduction of p16INK4A gene.
Sumitomo K; Shimizu E; Shinohara A; Yokota J; Sone S
Int J Oncol; 1999 Jun; 14(6):1075-80. PubMed ID: 10339660
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effect of adenovirus-mediated p16INK4a gene transfer on the proliferation of lung cancer cell line.
Lee JH; Lee CT; Yoo CG; Hong YK; Kim CM; Han SK; Shim YS; Carbone DP; Kim YW
Anticancer Res; 1998; 18(5A):3257-61. PubMed ID: 9858892
[TBL] [Abstract][Full Text] [Related]
18. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
[TBL] [Abstract][Full Text] [Related]
19. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication.
Shimamoto T; Ohyashiki JH; Hirano T; Kato H; Ohyashiki K
Oncol Rep; 2004 Aug; 12(2):389-95. PubMed ID: 15254707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
